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Abstract
Head and neck squamous cell carcinomas arise from the mucosa of the upper 
aerodigestive tract and is often driven by risk factors like tobacco and alcohol 
consumption. Most of the time patients present with locally advanced stages and 
the outcome is poor, despite recent advances in multi-modality treatment. The 
epidemiology of the disease has changed over the last decade with the introduction 
of a separate clinical entity; Human Papillomavirus (HPV) associated head and 
neck cancer. The tumorigenesis is different from that of tobacco and alcohol-driven 
malignancies. These tumors have a better response to treatment owing to their 
inherent genetic makeup and carry an excellent prognosis. The current school of 
thought is to reduce the long-term morbidities associated with various treatment 
modalities, as these patients tend to survive longer. The best management of HPV-
associated oropharyngeal cancer is under active investigation.
Keywords: human papilloma virus, oropharyngeal cancer,  
squamous cell carcinoma, treatment, prognosis
1. Introduction
HPV is currently a well-recognized and emerging risk factor for head and neck 
squamous cell carcinoma. HPV associated oropharyngeal carcinoma have distinct 
clinical behavior and outcome. This led to a paradigm shift in the research and trend 
towards De-escalating treatment strategies. The rationale of these trials is to prove that 
the de-intensified treatment modality has same efficacy with less morbidity compared 
to standard of treatment. This chapter tries to elaborate on the epidemiology, onco-
genesis, testing for HPV, treatment approaches and different clinical trials addressing 
the issue.
2. Epidemiology
Oropharyngeal carcinoma represents 0.9% of all cancers and its incidence 
is increasing with an estimate of 173,495 new cases in 2018 [1]. Epidemiological 
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studies have demonstrated that there has been a reduction in the incidence of 
laryngeal, hypopharyngeal, and oral cavity cancers since 1980, following a reduc-
tion in tobacco use in developed countries [2]. Oropharyngeal cancer incidence 
initially remained constant, then started rising [2, 3]. Later it was correlated to 
HPV-associated cancers in the tonsillar region and base of the tongue. There is 
a geographical variation in the incidence of oropharyngeal carcinoma with the 
increasing incidence of HPV associated cancers in the developed countries [4]. 
Among men the rising incidence of HPV associated oropharyngeal cancer was 
noticed in the United States, Australia, Canada, Japan and Slovakia and among 
women it was noticed in Denmark, Estonia, France, Netherlands, Poland, Slovakia 
and United Kingdom [4]. These patients tend to be younger and follow a biphasic 
distribution, which peaks around 30 and 55 years [5]. Male gender preponderance 
has been noted in many studies. In the ICON-S database median age of the HPV 
positive cases was 57 years and 84% of patients were male [5].
3. Clinical characteristics of HPV associated oropharyngeal cancer
HPV-associated Oropharyngeal Squamous cell Carcinoma (OPSCC) has 
different demographic and biological features when compared to HPV negative 
cancers [6]. These patients tend to be younger, with little or no tobacco expo-
sure, and associated with certain sexual behaviors like oral sex. They have dif-
ferent molecular alterations. Table 1 shows a comparison between clinical and 
biological profiles of HPV positive and HPV negative oropharyngeal carcinoma. 
The synergetic mechanism of HPV with tobacco and alcohol is unknown. The 
subset of OPSCC patients with significant smoking history may harbor TP53 
and EGFR mutations and their outcomes are similar to HPV negative head and 
neck cancers.
Characteristics HPV positive HPV negative
Age younger older
Gender 3:1 men 3:1 men
Socioeconomic status high low
Risk factors sexual behavior tobacco, alcohol
Co factors immunosuppression, marijuana use diet, hygiene
Incidence increasing decreasing
Survival better worse
Predilection site tonsil, base of tongue none
Histology basaloid/poorly differentiated keratinized
T-Stage lower T-stage higher T stage
Nodal status higher, often cystic nodes lower
Field cancerization unknown present
Genetics P53 inactivated by E6 P53 is mutated
Rb inactivated by E7 Rb inactivated by cyclin 
D1Amplification
P 16 over expressed Inactivation of p 16
Table 1. 
Major differences between HPV positive and negative oropharyngeal cancers.
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4. Human papillomavirus and carcinogenesis
A systematic review by Kriemer et al. has described the presence of HPV DNA in 
head and neck cancers [7]. Approximately 150 HPV subtypes have been reported. 
HPV 16 is associated with >90% of HPV associated oropharyngeal cancers [7]. HPV 
is a circular, double stranded DNA virus of 55 nm. Multiple sexual partners and/
or higher frequency of oral sex may increase the risk of HPV infection and later 
malignant transformation. Tonsillar crypts provide large epithelial surface and deep 
invaginations of the mucosal surface are thought to favor the capture and process-
ing of viral antigens. The epithelial basal cells are the target cells of the virus, where 
the viral DNA undergoes uncoating and is transported to the nucleus. In high risk 
HPV infection E6 and E7 proteins are produced from the supra basal layers. In HPV 
induced carcinogenesis, E6 and E7 oncoproteins deregulates cell cycle and apoptosis 
by acting on p53 [8]. P53 is a tumor suppressor gene which controls G1 transition to S 
phase in the cell cycle at G1 check point by inducing the expression of cyclin inhibi-
tors p16, p21 and p27 which in turn will block cyclin dependent kinases and progres-
sion of the cell cycle at G1/S transition. Inactivation, of p53 gene causes increased cell 
proliferation. Rb family of proteins governs the check point between G1 and S Phase. 
In normal cell cycle hypo phosphorylated Rb forms a complex with E2F and makes it 
unavailable for the DNA synthesis. E7 oncoprotein inactivate Rb family of proteins 
that causes over expression of E2F thereby produces increased cell proliferation [9].
5. Principles of HPV testing for oropharyngeal carcinoma
All patients diagnosed with OPSCC should undergo testing for HPV status. 
Biopsy from the primary lesion or FNAC from an involved node is sufficient for 
HPV testing. The gold standard is the demonstration of HPV E6/E7 mRNA expres-
sion in clinical specimens, which is often impractical. Demonstration of HPV 
DNA, by polymerase chain reaction (PCR), has high sensitivity, but specificity 
is low as cross-contamination can occur. In situ hybridization (ISH) technique 
allows the identification of a single viral copy and is more specific. In the HPV 
carcinogenesis, E7 mediated Rb inhibition leads to induction of demethylases 
resulting in overexpression of p16INK4A, which is a cyclin-dependent kinase inhibi-
tor. Hence the immunohistochemistry (IHC) test for P 16 is used as a surrogate 
marker for HPV status. Various methods for testing the HPV status is summarized 
in Table 2. Infection with non-HPV subtypes or low viral copy numbers cannot 
be detected by IHC and there can be a 7% disparity between HPV ISH and IHC 
reports. In the case of an equivocal P16, further testing by ISH can clarify the HPV 
status. Work up for patients includes thorough history taking, with documenta-
tion on pack-years smoked, and clinical examination (inspection, palpation, and 
endoscopy evaluation to see the extent of the lesion). Imaging using CT or MRI 
Tumor tissue Serum
• Testing for viral load(Viral DNA) In situ-hybridization • Antibody testing  
(Cumulative viral load) L1
Polymerase Chain Reaction Capsid protein
• Gene expression E6,E7 mRNA • Expressed oncoprotein E6, E7
• Surrogate Immunohistochemistry-P16  
Table 2. 
Various methods used for testing HPV status.
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Clinical and Pathological T categories
• T1 Tumour 2 cm or less in greatest dimension
• T2 Tumour more than 2 cm but not more than 4 cm
•  T3 Tumour more than 4 cm in or extension to lingual surface of epiglottis
• T4 Tumour invades any of the following: larynx, deep/extrinsic muscle of tongue(genioglossus, hyoglos-
sus, palatoglossus, and styloglossus), medial pterygoid, hard palate, mandible, lateral pterygoid muscle, 
pterygoid plates, lateral nasopharynx, skull base; or encases carotid artery
Clinical N categories
N0 No regional lymph node metastasis
N1 Unilateral metastasis, in lymph node(s), all 6 cm or less
N2 Contralateral or bilateral metastasis in lymph node(s), all 6 cm or less in greatest dimension
N3 Metastasis in lymph node(s) greater than 6 cm in dimension
Clinical
Stage I T1,T2 N0,1 M0
Stage II T1,T2 N2 M0
T3 N0,N1,N2M0
Stage III T1-T4 N3 M0
T4 Any N M0
Stage IV Any T Any N M1
Pathological N categories
Nx-regional nodes cannot be assessed
pN0-No regional lymph node metastasis
pN1-Metastasis in 4 or few lymphnodes
pN2-Metastasis in more than 4 lymphnodes
There is no T4b in the current classification and carcinoma in-situ is removed as there is absence of a distinct 
basement membrane in the epithelium of Waldeyers ring.
Extra capsular extension is not included in the pathological classification and there is no pN3 status.
Table 3. 
New classification for HPV positive carcinoma oropharynx based on AJCC Cancer Staging Manual, 8th [11].
neck aids in staging detects regional lymphadenopathy including retropharyngeal 
nodes. MRI neck in treatment position is particularly useful in delineation of the 
primary lesion for radiotherapy planning. The primary lesions of HPV positive 
OPSCC often had well-defined borders on imaging with a cystic nodal disease with 
or without necrosis. A chest X-ray is advisable to assess the baseline pulmonary 
function. Additionally, they need a dental evaluation for radiotherapy planning. 
All patients should undergo nutrition, speech, and swallowing evaluation, and 
smoking cessation counseling should be given if needed. Pre-anesthesia workup is 
needed if planning for surgery.
6. New staging system
As the number of HPV-associated OPSCC increased the 7th AJCC staging system 
lost its ability to differentiate between stages. There was an overlap of survival 
among different stages of HPV positive oropharyngeal carcinoma. Based on 
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accumulating evidence of prognostic value for HPV-positive OPSCC new staging 
system was refined [5, 10]. The new AJCC 8th staging system for HPV positive 
oropharyngeal carcinoma is summarized in Table 3 [11].
7. HPV status and treatment response
There are many factors attributed to the survival advantage for p16 positive 
oropharyngeal carcinoma. Many of the patients are younger, they have fewer 
comorbidities and less chance of field cancerization given reduced smoking his-
tory. HPV-positive tumours may harbour fewer or different genetic alterations. 
HPV-positive tumours have higher radio sensitivity, due to compromised DNA 
repair capacity [12]. Other studies have reported intrinsic radiation sensitivity and 
increased apoptosis following radiation exposure [13]. The immunologic response 
may play a role in the improved response to radiotherapy and chemotherapy in 
HPV-positive tumors.
The survival advantage noted for HPV positive OPSCC in the radiotherapy 
setting has been summarized in Table 4. Retrospective analysis of the HPV positive 
subgroup in the RTOG 0129 trial reported a strong association between HPV status 
and good survival [19]. They risk stratified the patients as having a low, intermedi-
ate, or high risk of death based on the combination of tumor HPV status, pack-
years of tobacco smoking, and cancer stage. In the low-risk group, which included 
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Major randomized trials that have reported survival benefit for HPV positive subset.
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HPV positive and non-smokers, 3-year disease-free survival (DFS) was 93% when 
compared to<50% in the high-risk group which included the HPV negative and 
smokers. The intermediate-risk group included HPV positive patients with smoking 
history and HPV negative non -smokers. This led to the thought for de-intensifi-
cation of the multimodality approach for low-risk category patients. In the post-op 
setting, the German radiation oncology group study showed a better correlation of 
HPV positive status with oropharyngeal carcinoma subsite and better outcomes in 
the patients undergoing adjuvant chemoradiation for locally advanced head and 
neck cancers [21]. Retrospective analysis of IMCL-9815 study, where patients were 
treated with radiotherapy with or without Cetuximab, the overall survival was 
better for p16 positive patients [22]. In the abovementioned trials, a better prognosis 
for HPV positive oropharyngeal carcinoma was independent of treatment modality. 
The association of HPV positive status with improved outcome was restricted to the 
oropharyngeal primary site [23].
8. De-escalating treatment intensity
The treatment options for early-stage OPSCC includes radical radiotherapy 
versus surgery (resection of the primary+/_ ipsilateral or bilateral neck dis-
section). For locally advanced oropharyngeal carcinoma primary treatment is 
radical chemoradiation or induction chemotherapy followed by radical chemo-
radiation with or without salvage surgery. The primary lesion and involved 
node with a margin are treated to a dose of 66-70Gy in 33–35 fractions and 
prophylactic nodal stations will receive 54 Gy in 30 fractions. With the introduc-
tion of intensity-modulated radiotherapy (IMRT) dose to dysphagia aspiration, 
related structures can be minimized. Cisplatin 80–100 mg/m2 once in 3 weeks 
is the standard concurrent chemotherapy schedule. For primary lesions of the 
oropharynx, surgical clearance is an issue, considering the complex anatomy and 
proximity to critical structures. Reconstruction is difficult and retropharyngeal 
nodes cannot be surgically removed. Bilateral neck dissection should be consid-
ered for lesions over the base of the tongue, soft palate, posterior pharyngeal 
wall, or tonsillar lesion invading the base of the tongue. Functional outcome is 
better with radiotherapy. In advanced-stage disease, surgery is often followed by 
adjuvant therapy which will lead to increased morbidity and decreased quality of 
life. Major factors deciding the treatment modality include performance status of 
the patient, location of the primary lesion, expertise available, morbidities asso-
ciated with each treatment option, and patient preference. Since HPV-positive 
oropharyngeal carcinoma patients tend to be younger and have prolonged 
survival, there is a potential to improve the quality of life through reducing the 
treatment-related toxicities. Application of this knowledge has led to multiple 
de-escalating strategies.
8.1 Minimally invasive surgery
The development of minimally invasive surgical techniques like transoral laser 
microsurgery (TLM) and transoral robotic surgery (TORS) has changed the surgi-
cal management for early oropharyngeal carcinoma. No prospective randomized 
studies are supporting the use of TORS over conventional surgery for oropharyn-
geal carcinoma. Small series report better swallowing outcomes in selected oropha-
ryngeal carcinoma patients treated with less invasive surgery with or without neck 
dissection, followed by adjuvant therapy [24]. Complications include postoperative 
haemorrhage and the need for temporary tracheostomy.
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ORATOR trial is the first phase 2 randomized trial comparing radiotherapy 
with transoral robotic surgery and neck dissection for early stage oropharyngeal 
squamous cell carcinoma [25]. Patients with T1–T2, N0–2 (≤4 cm) OPSCC tumor 
types were randomized to radiotherapy arm (70 Gy, with chemotherapy, if N1–2) 
or TORS plus neck dissection (with or without adjuvant chemoradiotherapy, based 
on pathology). In the surgery arm, 24% of patients received postoperative chemo-
radiotherapy. The initial report showed swallowing related quality of life score was 
better in the radiotherapy group after one year follow up. The ongoing ORATOR II 
trial is testing the overall survival between radiotherapy arm versus surgery [26].
Few other trials are assessing whether the swallowing function can be improved 
following minimally invasive surgery like Trans Oral Robotic Surgery (TORS) and 
to prove non-inferiority of reducing the intensity of adjuvant treatment in terms of 
overall survival. Table 5 shows de-intensification trials after surgical intervention. 
The aim of the ECOG 3311 study was to find out whether the dose of adjuvant radio-
therapy can be reduced in the intermediate risk patients [27]. 2-year Progression free 
survival was not affected by observation alone in the low risk group and reduced dose 
radiotherapy in the intermediate risk group. Pathos trial examines whether swal-
lowing function is better in patients undergoing transoral resection of HPV-positive 
OPSCC with reduced adjuvant treatment and results are awaited [28]. The rationale 
behind ADEPT trial is to find out is it safe to avoid concurrent chemotherapy in 
patients with extracapsular extension following minimally invasive surgery [29].
In the ECOG 3311 trial, the negative margin was defined as 3 mm or greater and 
adjuvant radiotherapy was offered to those with, <3 mm margin [27]. For transoral 
resection, the chance of positive margin is likely for the base of tongue tumors than 
Tonsillar tumors. In transoral laser microsurgery, the tumor may be removed in 
multiple pieces and it may be difficult to commend on the margin status. In many 
recent studies, the margin is generally considered clear unless involved [24].
Trial Phase N Inclusion criteria 





ECOG 3311[27] II 511 resectable stage 
III–IVB A.Low risk- 
observation 
B.Intermediate risk- 









PATHOS trial [28] III 1100 resectable T1–T3, 
N0–2b. excludes 
active smokers with 
N2b disease
Intermediate risk-









III 500 resectableT1–4a 
with negative 
margin pN positive 
with ECE
RT 60Gy/30 
fractions or RT 
60Gy/30 fractions + 
weekly Cisplatin
Awaited
TORS:Trans oral robotic surgery; ECE: extracapsular extension.
Table 5. 
Trials addressing the role of minimal invasive surgery and reduced dose radiotherapy.
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Currently, it is proven that the number of involved nodes is more prognostic 
than extranodal extension in resected oropharyngeal carcinoma and has been 
incorporated in the pathological staging of AJCC 8th edition [30]. Some authors 
have tried omitting chemotherapy in high-risk patients with extranodal extension, 
to reduce the toxicity associated with triple modality treatment [31]. In the absence 
of evidence, this practice is not recommended. Routman has reported resected 
oropharyngeal cancer patients without high-risk features have an 11% risk of 
failure, whereas those with ECE had a 53% risk of recurrence [32]. This implicates 
the role of adjuvant radiotherapy in this setting. The role of adjuvant radiotherapy 
in resected HPV positive oropharyngeal cancer with intermediate-risk patients 
(PNI, LVI, T3 to T4, or N2 diseases) needs further clarification. The basic principle 
of oncology is to limit the number of modalities used for treatment to reduce long 
term morbidities. Long-term data are needed for further refinement of the best 
management strategy.
8.2 Non-surgical de-intensification strategies
De-intensification strategies employing reducing the dose or volume of radiation 
therapy have the potential to reduce gastric tube dependence, osteoradionecrosis, 
dysphagia, xerostomia, dental decay, hypothyroidism, carotid stenosis, etc. which 
include the following
a. Replace Cisplatin with Cetuximab (along with radiotherapy).
b. Neoadjuvant chemotherapy followed by decreased radiotherapy dose/volume
c. Chemo-radiation with decreased radiotherapy and chemotherapy doses.
d. Omitting chemotherapy.
e. Protons instead of photons.
8.2.1 Replace cisplatin with cetuximab
In the subset analysis of Bonners trial, the benefit of Cetuximab plus RT was 
restricted to the oropharyngeal subsite [33]. It was later hypothesized to replace 
Cisplatin with Cetuximab in this favorable group. The three major trials which 
looked into this aspect were RTOG1016, De-Escalate HPV, and the TROG study 
(Summarized in Table 6).
Results from both RTOG 1016 trial and De-Escalate HPV trial show that HPV 
positive disease has a good prognosis, there was no difference of toxicity between 
the two arms, better overall survival and less recurrence with Cisplatin plus RT arm 
and Cisplatin plus RT remains the standard of care in low-risk HPV positive disease. 
The result of the TROG 12.01 study is awaiting [36].
8.2.2 Neoadjuvant chemotherapy followed by decreased radiotherapy dose/volume
E1308 was a phase II trial, in which patients were selected to reduced RT dose based 
on complete clinical response to neoadjuvant chemotherapy with Cisplatin + Paclitaxel 
+ Cetuximab [37]. Those who achieved complete clinical response was treated to an 
RT dose of 54Gy in 27 fractions, 5 days a week with concurrent cetuximab for 6 weeks, 
and those patients who achieved a partial response or stable disease was treated to a 
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dose of 69.3 Gy in 33 fractions, 5 days a week with concurrent Cetuximab for 7 weeks. 
After a median follows up of 35.4 months, the 2-year progression-free survival was 
80% in the reduced RT group with improved swallowing and nutritional status.
The Quarterback trial is another trial that is looking into this aspect. It is a phase 
III randomized trial comparing reduced dose (IMRT,56Gy in 28 fractions with 
concurrent Carboplatin weekly) and standard-dose radiotherapy (IMRT,70Gy 
in 35 fractions with concurrent Carboplatin weekly) for locally advanced HPV 
oropharyngeal carcinoma after neoadjuvant chemotherapy with TPF (Cisplatin, 
Docetaxel, and 5-Fluorouracil) regimen [38]. The primary endpoint is progression-
free survival and results are awaited.
Another study has tried reducing the radiation therapy volume, keeping the 
radiation dose unchanged [39]. Following induction chemotherapy (Cisplatin, 
Paclitaxel, Cetuximab ± Everolimus), patients with >50% reduction received 
radiotherapy to gross disease only. Whereas patients with <50% reduction received 
radiotherapy to gross disease and next elective nodal station. Two -year PFS was 
93.1% in the responders versus 74% in the non-responders.
In the OPTIMA trial, both dose reduction and volume de-escalation were tried 
where radiation was limited to the first echelon of uninvolved nodes [40]. After 
3 cycles of neoadjuvant chemotherapy (Carboplatin+ nab-Paclitaxel), low-risk 
patients with ≥50% response received 50 Gy RT, low-risk patients with 30%–50% 
response, and high-risk patients with ≥50% response received 45 Gy RT + concur-
rent chemotherapy and patients with the lesser response received 75Gy + concur-
rent chemotherapy. Two-year progression survival was not compromised compared 
to historical control.
8.2.3 Chemoradiation with decreased radiotherapy and chemotherapy doses
In a phase II trial, favourable risk HPV associated oropharyngeal carcinoma 
patients were randomized to receive 60Gy intensity-modulated radiation therapy 
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Trials replacing Cisplatin with Cetuximab.
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with concurrent weekly Cisplatin (30 mg/m2) followed by biopsy from the primary 
site and planned neck dissection of the initially involved site [41]. The primary 
endpoint of the study, pathological complete response was 86% and was associated 
with less toxicity. Few drawbacks of this study are that they included early-stage 
cases, short follow-up (14 months), and planned neck dissection which was unnec-
essary in some patients. In the follow up study, with the same IMRT dose 60 Gy in 
30 fractions, multiple chemotherapy options were there (weekly regimens with 
Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250 mg/m2 (second choice), 
Carboplatin AUC 1.5 and paclitaxel 45 mg/m2) and chemotherapy was omitted for 
patients with T0-2 N0-1 disease, ≤ 10 pack-years smoking history [42]. The neck 
dissection was advised based on positive PET/CT done after 10–16 weeks. The 
results are awaited.
8.2.4 Omitting chemotherapy
In the HN 002 trial, patients with stage T1- T2, N1-N2b or T3, N0-N2b, p16 positive 
oropharyngeal carcinoma patients were randomized to receive either IMRT 60 Gy/30 
fractions over 6 weeks, or IMRT with concurrent weekly Cisplatin 40 mg/m2 [43]. 
Estimated 2-year survival and late toxicity were similar and acute toxicity were more 
in the chemotherapy arm.
8.2.5 Protons instead of photons
The goal of the trial was to compare the side effects of 2 radiation treatments; 
intensity-modulated photon beam therapy 70Gy(RBE) in 33 fractions, with inten-
sity-modulated proton beam therapy, 70Gy(RBE) in 33 fractions. The estimated 
study completion date is 2024 [44].
9. Unknown primary with cervical node metastasis
If p16 positive in lymph node specimen, it is staged as per p16 positive orophar-
ynx carcinomas and treated accordingly.
10. Immunotherapy
Immunotherapy as sole therapy has reported a delay in progression in metastatic 
HPV positive oropharyngeal carcinoma [45]. Combining Checkpoint inhibitors like 
anti-programmed cell death 1 (PD-1) with tumor vaccine has some shown benefit 
in a recurrent setting in phase II trials [46].
11. Post-treatment surveillance
Following the completion of treatment, the patient should be evaluated clini-
cally once in 3 months for the initial 2 years, once in 6 months for 5 years, and 
yearly thereafter. Persisting symptoms, radiating pain to the ear, etc. warrants 
local recurrence. Negative PET/CT scan obtained between 3 and 6 months after 
completion of treatment and at 12 months post-treatment is associated with a good 
prognosis. Considering the low recurrence rate in HPV positive OPSCC and the cost 
involved, it’s not a routine investigation that is followed.
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12. Treatment of recurrent and metastatic disease
Salvage surgery or irradiation if feasible should be considered for recurrent 
disease. Palliative chemotherapy with platinum doublets can be considered if local 
treatment not feasible. Clinical trials are ongoing with targeted agents, immuno-
therapy as sole treatment versus combination therapy.
13. Conclusion
HPV associated oropharyngeal carcinoma is on the rise. A lot of research is hap-
pening in this field to refine the best treatment for this separate clinical entity with 
the vision to reduce long term morbidities. Mature data with long term follow up 
is needed to change the current practice. At present, HPV-positive oropharyngeal 
carcinoma patients should not be treated with de-intensification protocols outside 
the clinical trial setting.
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